Panel Discussions
Tuesday, October 26
7:30 a.m. - 12:15 p.m.
MDIF 2010 Topics
NeurovascularSponsored by: Stradling Yocca Carlson & RauthTuesday, 7:30 - 8:30 a.m.
The neurovascular Interventions business has been largely shaped by technologies developed in California. This panel has representatives from all of the major neurovascular interventions business as well as several emerging start-up technologies. The panel will focus on why the neuro business has flourished in California and what technologies will shape the future of neurovascular intervention.
Rob Abrams: Operating Partner, Sanderling Ventures Rob joined Sanderling as an Operating Partner in April 2008, where he currently serves as CEO of Pulsar Vascular, Inc. & Theregen, Inc.
Richard Cappetta: President and Chief Executive Officer, MicroVention
Mr. Cappetta was appointed President and Chief Executive Officer of MicroVention, Inc. in April 2008 having previously served as Sr. Vice President for Worldwide Sales.
More...
Bruce Feuchter: Shareholder, Stradling Yocca Carlson & Rauth
Bruce Feuchter’s practice is centered on the fields of corporate securities, intellectual property and general finance transactions. He handles organizational matters for early stage and mature companies, private and public financing, mergers and acquisitions, venture capital investments, and technology licensing strategies. He also works with new companies in formation.
More...
Earl H. Slee – Vice President of Advanced Research and New Business Development, ev3
Earl Slee is a medical device executive with over 25 years of experience leading product development in companies with strong growth. As Vice President of Research and Development at ev3 Neurovascular, an Irvine company focused on endovascular treatments for hemorrhagic and ischemic stroke, revenue grew to $220M over the last 12 years. More...
Bob Stern - Micrus Endovascular
Mr. Stern served as President and Chief Operating Officer of Micrus Endovascular NASDAQ (MEND) from November 2007 until the company’s sale to Johnson and Johnson in September 2010.
More...
George Wallace: Managing Partner - Intersect Partners
George Wallace is currently the Managing Partner for Intersect Partners, LLC, a partnership between George, a medical device executive and Andrew Cragg, M.D., a practicing Interventional Radiologist. Intersect Partners was formed as a research and investment vehicle dedicated to research and development for medical device companies focused on solutions to large and unmet medical needs.
More...
Built to Succeed: Best Practices for Medical Device Start-up CompaniesSponsored by: ContinuumTuesday, 7:30 - 8:30 a.m.
How do you cross the chasm from having a promising technology or idea to delivering a commercially viable product? There is no surefire formula for this transition, but there are some key elements that need to be managed if the product is going to be developed and delivered successfully. Every start-up company needs to leverage its unique skill sets and determine what should come from within the organization (what’s great inside), and what should come from the outside (what do we need from others) to insure the device gets delivered to the market effectively.
Continuum will host a discussion with serial entrepreneurs and development experts who will share their perspectives on what enables a company to succeed as they work to move from an idea to a commercially viable device.
Specific topics that will be addressed include:
- Developing a commercialization strategy
- Managing the development process
- Managing risk
- Leveraging your organization
- Managing strategic relationships
Darrel Drinan: Co-Founder and CEO, PhiloMetron
PhiloMetron is a medical technology accelerator located in San Diego that is developing novel therapeutic solutions for chronic disease and quality of life conditions utilizing the Company's novel and proprietary technology.
More...
Tom Merle - Chief Development Officer, Continuum Advanced Systems
Tom brings a holistic approach to product development and innovation. He has led the growth of the Advanced Systems team at Continuum, working at the intersection of technology, systems, and human-centered design. More...
Thomas E. Wood, Partner, Elm Street Ventures
Tom Wood is an experienced medical device industry executive and serial entrepreneur. His 30 years in the medical device business included 17 years with US Surgical Corporation where he served in a number of positions including Vice President/General Manager, Life Sciences Division and Vice President Market Strategies.
More...Healthcare ITTuesday, 7:30 - 8:30 a.m.
President Obama has clearly outlined information technology as one of the cornerstones of healthcare reform. This panel will explore how changes in information technology management is changing hospital practices and how start-up technologies are supporting the dynamic changes occurring in this segment.
Robert Cass - CEO, Perminova
Robert Cass is the co-founder and CEO of Perminova Inc. as well as the principal architect for its online cardiovascular and surgical information systems.
More...
Michael Hedge - Partner, K&L GatesMichael Hedge is a partner in the firm's Orange County office. His practice focuses on securities, mergers and acquisitions, corporate finance, venture capital, corporate governance and commercial transactions.
Bob Holmen, Managing Director - Miramar Venture PartnersBob Holmen is a Managing Director and co-founder of Miramar Venture Partners. Formed in 2001, Miramar invests in early-stage technology companies, with an emphasis on Southern California opportunities.
Loretta Mann, Director Information Technology Services for St. Joseph Hospital of Orange. Loretta is currently responsible for overseeing and coordinating all administrative, academic and clinical technology, telecommunications, wide area networking, local area networking, desktop support, IT security, disaster recovery planning, applications training and support, and applications implementation. She also serves as Director of Technology for the Health Systems Home Health Services.
Andre Vovan, MD, MBA - Chairman, Chief Medical Officer, Mitochon Systems, Inc.
Andre Vovan, MD MBA, Founder, Chairman and Chief Medical Officer of Mitochon Systems since 2006. Mitochon creates zero-cost virtual medical communities that enable integrated heath information delivery among independent physician practices and their patients.
More...CardiovascularSponsored by: Bingham McCutchenTuesday, 8:45 - 9:45 a.m.
Mark C. Bates, M.D., F.A.C.C., F.S.C.A.I.: Founder and Chief Executive Officer -
Nexeon MedSystems
Mark C. Bates, M.D., F.A.C.C., F.S.C.A.I., founder and CEO of Nexeon MedSystems, is a successful entrepreneur and thought leader in cardiovascular medicine. Currently the co-director of one of the largest vascular centers in the U.S. and a full West Virginia University professor of Medicine and Surgery, Dr. Bates has more than 20 years of interventional cardiology experience during which time he has performed or supervised thousands of coronary and peripheral procedures.
More...
Richard Ferrari - Managing Director, De Novo Ventures
Rich has been a successful CEO of several medical technology companies, both prior to and after co-founding De Novo in 2000. Following De Novo’s investment in CryoVascular Systems, Rich became CEO, growing the initial 5 person start up team to a company of 20 employees. He was instrumental in developing the clinical and product strategies and hiring the executive team.
More...
Robert C. Funsten: Partner, Bingham McCutchen
Robert Funsten's corporate, M&A and securities practice focuses on advising life sciences companies, including medical device , pharmaceutical and biotechnology firms. Rob is a co-chair of the firm’s life sciences practice. More...
Mitch C. Hill: Vice President and Chief Financial Officer, Cameron Health
Mitch currently serves as CFO of Cameron Health, Inc., a venture capital-backed medical device company developing the world’s first subcutaneous implantable defibrillator. Prior to Cameron, Mitch served as CFO of Visiogen Inc., a venture capital-backed medical device company focused on the cataract replacement lens market, which was acquired by Abbott Medical Optics in late 2009.
Larry Wood - Corporate Vice President, Transcatheter Valve Replacement, Edwards Lifesciences
Larry L. Wood is corporate vice president, Transcatheter Valve Replacement of Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring. More...
How to Spend Your IP Dollars EffectivelySponsored by: Knobbe Martens Olson & BearTuesday, 8:45 - 9:45 a.m.
What do typical medical device start-ups budget for intellectual property expenses? Why is IP often the largest expense of a successful medical device company? What are proven strategies and methods for effectively managing an IP budget?
Come hear an expert panel discuss these and other practical and immediately useful issues relating to managing an IP budget. The panel includes Erik van der Burg, a serial entrepreneur and co-founder of Siesta Medical; Charles Warden, a medical device venture investor since 1992 and Managing Director of Versant Ventures; and Gerard von Hoffmann, a partner at Knobbe Martens with over 25 years of experience in medical device intellectual property matters.
Sabing Lee - Partner, Knobbe Martens Olson & Bear, LLP (moderator)
Mr. Lee is a partner in KMOB's Orange County office.
Mr. Lee’s practice includes strategic patent procurement, patent portfolio management, general counseling on infringement and licensing issues, and other related issues. More...
Erik van der Burg - Chairman/CTO, Siesta Medical, Inc.
Mr. van der Burg is Chairman, CTO and Co-founder of Siesta Medical, which is developing surgical treatments for obstructive sleep apnea. More...
Gerard von Hoffmann - Partner, Knobbe Martens Olson & Bear
Mr. von Hoffmann is a partner in KMOB's Orange County office. He specializes in client practice in the medical device industry including offensive and defensive competitive strategies, infringement studies, financings, strategic transactions and patent prosecution. More...
Charles Warden - Managing Director, Versant Ventures
Mr. Warden has been an active medical device venture investor since 1992. He works closely with entrepreneurial device companies from inception along the path to success. More...
DiabetesSponsored by K&L GatesTuesday, 8:45 - 9:45 a.m.
The largest potential health epidemic in the U.S. is the alarming rise of diabetes. The technology that defines the treatment of this disease is evolving at an equally fast pace. This panel will examine the development of technologies that will be used to measure and treat diabetes in the future.
Louis C. Cullman (Chip) - Partner, K&L Gates
Chip a partner in the Orange County office of K&L Gates LLP specializing in intellectual property (IP) law where he manages the transactional IP group. His practice has a strong life sciences focus and concentrates on transactional IP for pharmaceutical and medical device companies.
More...
John D. Gerace - Entrepreneur in Residence, Life Technologies, Inc.
John Gerace has recently been appointed “Entrepreneur in Residence” at Life Technologies (NASDAQ: LIFE) chartered to start a new business unit or spin out a new business that leverages LIFE assets. He is also a board member for the
Iacocca Family Foundation - a non-profit organization with the objective of accelerating the discovery of a cure for Type-1 Diabetes (T1DM).
More...
Terrance H. Gregg - President and CEO, DexCom, Inc.Mr. Gregg is President and CEO of DexCom, Inc. He is also currently a Special Venture Partner with Galen Partners, a private equity firm specializing in the healthcare industry. In 2002 he retired as President of Medtronic MiniMed, a world leader in diabetes management systems. He became President and Chief Operating Officer of MiniMed, Inc. in 1996 and was instrumental in Medtronic's $3.4 billion acquisition of MiniMed in 2001.
More...
William H. Markle - President and CEO, GluMetrics, Inc.
Mr. Markle has over 25 years experience in management of high-tech medical device companies focusing on the Critical Care marketplace (Baxter, Edwards Life Sciences, American Hospital Supply).
More...
John Mastrototaro, Ph.D. - Vice President, Global Research and Development,
Medtronic Diabetes
John is an internationally renowned expert in diabetes technology and has authored dozens of publications in peer reviewed journals on original clinical research and consensus reports. He is an invited guest lecturer at both domestic and international professional diabetes meetings. More...
AestheticsSponsored by: Dorsey & WhitneyTuesday, 10:00 - 11:00 a.m.
The treatment opportunities in aesthetic medicine have exploded. From Botox to liposuction, to laser treatment, and implants - it is expected that the technologies developed in the coming five years will dramatically eclipse the technologies that have shaped this dynamic medical device sector in the past 20.
Greg Bendis - Founder and Business Director, Reviticell
Reviticell has two subsidiary companies for which it is the management company - Revitifill, LLC, which develops and produces Stem Cell Enhanced Therapies, and Revitiderm, LLC, which develops and produces Growth Factor Enhanced Treatments.
David Endicott: Corporate Vice President and President, Allergan Medical
David J. Endicott was appointed Corporate Vice President and President of Allergan Medical in July 2010. Mr. Endicott has been with Allergan 24 years, during which time he has served in a number of domestic and international roles.
More...
David Hayes: Partner, Dorsey & Whitney
Mr. Hayes is a partner in the Corporate group and co-Chair of both the Licensing and Technology Commerce and Technology Commerce practices. More...
Michael Moretti - Publisher, Medical Insight
Michael Moretti has served as a medical industry analyst and strategic advisor for more than 20 years.
More...M&A UpdateSponsored by: Latham & WatkinsTuesday, 10:00 - 11:00 a.m.
This panel will focus on the factors that distinguish a medical device company from its competition at the exit transaction stage and how companies can plan ahead to make themselves more attractive to potential underwriters and acquirors. The panelists, all of whom have extensive experience with IPOs and M&A transactions in the medical device and life science industries, bring a variety of perspectives to this discussion, with expertise ranging from investment banking to accounting and the law. The objective is to provide insights to leaders of early and medium-stage private companies as to how they can make their companies more competitive in the marketplace for exit transactions, as well as potentially saving significant time and money when the time for an exit comes.
David Allen - Partner, Latham & Watkins
David Allen is a partner in the Corporate Department of the Orange County office of Latham & Watkins. David’s practice focuses on capital markets, mergers and acquisitions, and general corporate and securities matters. More...
Glenn Bier - Partner, PricewaterhouseCoopers, LLP
Glenn is a partner in the Orange County office of PricewaterhouseCoopers. During his career, Glenn has worked extensively with clients in the medical device, biotechnology, software, semiconductor, internet, telecommunications and entertainment industries. More...
Jed Cohen: Managing Director, Leerink Swann
Jed Cohen is a Managing Director in Leerink Swann’s investment banking practice, focused on the medical technology industry.
More...
Shayne Kennedy: Partner, Latham & Watkins
B. Shayne Kennedy is a partner in the Orange County office of Latham & Watkins and serves as the Co-Chair of its Corporate Department. Mr. Kennedy’s practice focuses on capital markets, general corporate representation and mergers and acquisitions. More...
When Enough is Enough: When & How to Push Back on the FDASponsored by: Alquest
Tuesday, 10:00 - 11:00 a.m.
FDA’s evidentiary requirements for safety and effectiveness of medical devices have changed drastically in just the last 12 months. So much so that manufacturers are scratching their heads at minimum, or going bankrupt at worst. When is enough, enough? A leading medical device regulatory expert covers a range of options facing manufacturers in today’s frustratingly arbitrary and ill-defined regulatory climate. Come ready to think about taking your best shot at regulatory success.
Linda Alexander - CEO, Alquest, Inc. Alquest is a clinical research organization and regulatory consultancy specialized exclusively in medical devices and biologics. More... Recent Advances in Medical Device Technology for the Detection and Treatment of Cancer Sponsored by: StatKingTuesday, 11:15 a.m. - 12:15 p.m.
The National Cancer Institute has reported declines in cancer deaths over the past ten years. This decline is due in part to new treatments and better screening methods for the disease. This session will address advances in the medical device arena for both the treatment and detection of various forms of cancer. An overview of the cancer diagnostics market will be given with emphasis on radiopharmaceuticals and molecular diagnostics.
Frederick Oliver Cope, PhD, FACN, CNS - Vice President for Pharmaceutical Research and Clinical Development, Neoprobe Corporation
Neoprobe is focused on developing and commercializing innovative biomedical products that meet the critical intraoperative, diagnostic and therapeutic treatment needs of patients and physicians. More...
Dennis W. King, PhD - President and CEO/Statistician, StatKing (moderator)
Dennis W. King is President of STATKING Consulting Inc., Cincinnati, OH. Over the past 30 years as a statistical consultant, he has provided expertise on experimental design and data analysis to hundreds of industrial, governmental and academic clients. More...
Comparative Effectiveness ResearchSponsored by: Ernst & YoungTuesday, 11:15 a.m. - 12:15 p.m.
Health care reform, comparative effectiveness and death panels: Separating myth from reality. In this presentation Dr. Fera will speak about the misconceptions and realities of comparative effectiveness. He will present goals and challenges for comparative effectiveness in the broader context of health care reform. Dr. Fera will discuss implications for device manufacturers.
William Fera, MD - Executive Director, Ernst & Young Health Care Advisory
Bill is an Executive Director in the Advisory Services practice and serves as the Clinical Transformation leader for Health Care clients. More...
Sustaining a Culture of Innovation and Growth: Talent Trends and Leading PracticesSponsored by: TriNetTuesday, 11:15 a.m. - 12:15 p.m.
Leaders often tell each other that “people are my company’s most important resource”. What are the “people practices” that help medical device companies create an environment where employees can sustain long-term innovation and growth ?
This panel will examine the talent strategies and practices used by growing medical device and similar companies to create and sustain innovation and growth. We expect to take up four key elements of successful talent strategies:
- Attracting the right people – how do we find, assess and hire the right people?
- Setting goals and managing performance -- Old-school annual reviews do not seem to help employees or managers innovate. What tools help great employees stay aligned with company objectives while promoting creativity and innovation?
- Compensating Correctly – How do winning companies reward innovation by individuals or teams?
- Developing leaders – What are the best ways to develop innovative individual contributors into company leaders?
The panel will discuss current practices and challenges in these areas, and share recent trends and data to deliver insight on these key questions.
James M. Corbett: Chief Executive Officer, Vertos Medical
Mr. Corbett joined Vertos Medical in November 2008 as President, Chief Executive Officer and Member of the Board of Directors. From 2001 to 2008, Mr. Corbett served as CEO and President of ev3, Inc., and was Chairman of the Board of Directors from 2007 to 2008.
More...
Burton M. Goldfield: President and CEO, TriNet
Burton M. Goldfield joined TriNet in 2008 and currently serves as president and chief executive officer. In this role, Goldfield is responsible for setting TriNet’s overall corporate strategy and directing business operations.
More... 
Richard Henson: Founder, CEO - Source Scientific, LLC
Mr. Henson is a Founder and CEO of Source Scientific, LLC, a medical instrument and device services firm in Irvine, California.
More...
John F. Ryan - Partner, ONSET VENTURES
John Ryan joined ONSET Ventures in 2008 after focusing throughout his career on the founding, building and financing of companies across many sectors of the healthcare industry at stages ranging from the earliest company formation to the largest industry leaders. More...
